Diagnosis and treatment of cholangiocarcinoma: A consensus from surgical specialists of China

Cai, Jian; Cai, Shou Wang; Cong, Wen-ming; Chen, Minshan; Chen, Ping; Chen, Xiao Ping; Chen, Yan Ling; Chen, Yi Fa; Dai, Chenyun; Huang, Qiang; Huang, Zhi; Jiang, Bo; Jiang, Bin; Jiang, K.; Li, Bo; Li, Zong Fang; Liang, Lihong; Liu, Bin; Liu, Hui Chun; Liu, Lian Xin; Liu, Qing Guang; Liu, Rong; Liu, Ying Bin; Lü, Jian; Lu, Shi Chun; Lü, Yi; Mao, Yi; Mei, Bin; Ni, Jun; Peng, Bao Gang; Qin, Xiao; Qiu, Yu; Wang, Guang Yi; Wang, Yaodong; Wang, Zhi Ming; Wan, Ren Hua; Wu, Ya Fu; Xing, Bao Cai; Xia, Feng; Xu, Ge; Yang, Jia Mei; Yu, Xiaofeng; Zeng, Yong; Zeng, Yong; Zhang, Bi Xiang; Zhang, Bin Hao; Zhang, Qi Yu; Zhang, Shui Jun; Zhang, Wan Guang; Zhang, Yong Jie; Zhang, Zhi Wei; Zhou, Dong; Zhou, Wei

doi:10.1007/s11596-014-1301-5

Cited by 19 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The guidelines were required to meet the following criteria: (i) The guidelines should covered diagnosis and treatment of iCC, pCC, or dCC at a minimum; (ii) Credibility, guidelines were those drafted by medical societies with or without government support. Nine guidelines were included in this review (11)(12)(13)(14)(15)(16)(17)(18)(19) (Table 1). Only the latest versions of the guidelines were included in the table, but the old versions of guidelines may be discussed as sources of evidence.…”

Section: Current Guidelines On CCmentioning

confidence: 99%

The current management of cholangiocarcinoma: A comparison of current guidelines

Cai

Cheng

Yang

et al. 2016

BST

View full text Add to dashboard Cite

Cholangiocarcinoma (CC) accounts for about 3% of all gastrointestinal tumors and is the second most common primary liver tumor. Quality guidelines on CC are needed to guide hepatobiliary surgeons. Here, current guidelines on CC were reviewed to provide useful information and suggestions to help institutes and organizations all around the world to draft better guidelines on CC. Literature databases were electronically searched to identify guidelines or consensus statements regarding CC published from 2002-2016. Nine guidelines were included in this review. Comparison of the current guidelines revealed several inconsistencies. Signs of conflicting views indicated a lack of high level evidence. More studies need to be conducted in areas of contention to help update the guidelines. Organizations and medical societies need to be encouraged to use standard evaluation measures, to restrict tumors to CC or iCC, pCC, or dCC specifically, to give recommendations in accordance with the equipment that is available for diagnosis and treatment in different counties, and to use an appropriate and consistent structure when establishing and drafting guidelines for CC.

show abstract

Section: Current Guidelines On CCmentioning

confidence: 99%

The current management of cholangiocarcinoma: A comparison of current guidelines

Cai

Cheng

Yang

et al. 2016

BST

View full text Add to dashboard Cite

show abstract

“…Due to the high frequency of diagnosis at a late stage, metastasis and recurrence, surgical treatment for CCA is associated with poor outcomes. The 5-year survival rate is 5-10% in patients with CCA (1). Therefore, understanding the molecular mechanisms involved in the tumorigenesis of CCA is a critical step for improving early diagnosis, reducing mortality, and developing effective targeted therapies.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of competing endogenous RNA networks associated with cholangiocarcinoma

Zhao

Qin

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is the second most common type of primary malignancy of the liver. Certain long non-coding RNAs (lncRNAs) have been demonstrated to have key roles in tumor pathogenesis by binding to microRNAs (miRNAs). However, the competing endogenous RNA (ceRNA) network of CCA remains to be fully determined. In the present study, the RNA expression profiles for CCA were downloaded from The Cancer Genome Atlas and further analyzed. A total of 318 differentially expressed (DE) lncRNAs, 87 DE miRNAs and 3,851 DE mRNAs were identified from 36 CCA samples and 9 adjacent non-tumor samples (for lncRNAs and miRNAs, fold change ≥2.5 and P<0.01; for mRNAs, fold change ≥2 and P<0.01). Further bioinformatics analyses were performed and the ceRNA network for CCA was constructed, which included 16 lncRNAs, 55 miRNAs and 373 mRNAs. Survival analysis of all genes in the network revealed that high expression of the mRNAs fucosyltransferase 4 (P<0.005) and huntingtin-interacting protein 1 related (P<0.001) has a positive impact on the overall survival of patients with CAA. Furthermore, the lncRNAs H19 and PVT1, and the miRNAs Homo sapiens (hsa)-miR-16-5p and hsa-miR-424-5p,

show abstract

“…Only complete surgical resection can be curative, but the majority of patients are diagnosed with unresectable advanced disease, including metastatic disease and locally advanced tumor, and they usually die within a year of diagnosis [ 2 – 4 ]. Overall, 5% of patients with cholangiocarcinoma have multifocal lesions, 50% have lymph node metastases, and 10–20% have distant metastases at the time of presentation, so that long-term survival cannot be achieved with surgical treatment [ 5 ]. From the clinicopathological view, the majority of these tumors are adenocarcinomas, and squamous cell carcinoma (SCC) of the biliary system is extremely rare.…”

Section: Introductionmentioning

confidence: 99%

Primary Intrahepatic Squamous Cell Carcinoma with Histological Collision of Adenocarcinoma and Squamous Cell Carcinoma: A Case Report

et al. 2018

View full text Add to dashboard Cite

Patient: Male, 82Final Diagnosis: Intrahepatic squamous cell carcinomaSymptoms: NoneMedication: —Clinical Procedure: —Specialty: OncologyObjective:Rare diseaseBackground:Cholangiocarcinoma is a rare, aggressive biliary tract malignancy. On histopathology, most tumors are adenocarcinomas, while squamous cell carcinoma of the biliary tract is extremely rare.Case Report:An 82-year-old male was admitted due to the detection of a space-occupying lesion at S6 of the liver. On abdominal dynamic computed tomography, there was an irregular mass with inhomogeneous density associated with mild delayed enhancement in the tumor’s peripheral zone, measuring approximately 22×25 mm, at S6, with secondary dilated biliary ducts of B6. Endoscopic retrograde cholangiopancreatography showed a severe stricture at B6. Brush cytology of B6 was positive for both adenocarcinoma and squamous cell carcinoma. Furthermore, mucous brushing cytology of the papilla of Vater was also positive for adenocarcinoma. Finally, the preoperative diagnosis of primary intrahepatic cholangiocarcinoma, combined with a cancer of the papilla of Vater, was made. The patient underwent both extended right lobectomy and pancreaticoduodenectomy. Histological examination showed that the majority (>99%) of this liver tumor was composed of keratinizing squamous cell carcinoma.Conclusions:Squamous cell carcinoma of the biliary tree is very rare, since the majority of biliary tree tumors are adenocarcinomas. Cholangiocarcinoma containing a squamous cell component has a poor prognosis. To the best of our knowledge, this is the first case report of a primary intrahepatic squamous cell carcinoma that presented as a solid tumor showing clear histological collision between adenocarcinoma and squamous cell carcinoma and was successfully treated with hepatic resection and achieved disease-free survival of more than one year.

show abstract

Diagnosis and treatment of cholangiocarcinoma: A consensus from surgical specialists of China

Cited by 19 publications

References 23 publications

The current management of cholangiocarcinoma: A comparison of current guidelines

The current management of cholangiocarcinoma: A comparison of current guidelines

Comprehensive analysis of competing endogenous RNA networks associated with cholangiocarcinoma

Primary Intrahepatic Squamous Cell Carcinoma with Histological Collision of Adenocarcinoma and Squamous Cell Carcinoma: A Case Report

Contact Info

Product

Resources

About